![](https://investorshub.advfn.com/uicon/522650.png?cb=1464431304)
Tuesday, August 11, 2020 1:34:44 PM
Nothing can change the facts that we are playing in a $2 Billion CNS market now, simple and easy. We are in the right direction to have $160 - $180M revenue annually just from CNS Adderall IR and Aderall XR.
We now know how fantastical these projections are. I read here every day how Elite has replaced TEVA in every Walgreen's across the known universe, yet the quarterly revenue for the entire Elite formulary is around $7M per quarter. This includes both Adderall IR and XR. You'd have to multiply the current quarter revenues by 6X to achieve your numbers. I'd be happy to be wrong, but I have realistic expectations. With a billion shares outstanding, there will need to be several multiples of current revenue to move the needle on share price in any meaningful way, and even that will likely be offset by further R&D spending with even more shareholder dilution. It should be obvious by now that the Adderalls alone have not changed and will not change the current trajectory of the company. It should also be obvious that Concerta is a long way off.
Meanwhile, with opioid ANDA's in tact, we could already be sitting at $100M in annual revenue. Ignoring this fact doesn't make it less true or less important. Nasrat is a failed CEO whose destructive decisions have had a major negative effect on this company's future. He doesn't deserve our blind respect. He has properly earned our deep suspicion about his motives and abilities.
Occam's razor: the simplest solution is most likely the right one.
Hanlon's razor: never attribute to malice that which is adequately explained by stupidity.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM